MAPK8 and familial pancreatic carcinoma: To understand the role and mechanism of JNK in PDAC, we treated (five) different well-characterized pancreatic cancer cell lines with JNK inhibitors SP600125 and JNK-IN-8 at concentrations between 0.5 and 20 μM, thus spanning a range more than 20-fold lower than that typically employed for in vitro studies with these compounds [14, 15, 16].